Interstitial lung disease progression after genomic usual interstitial pneumonia testing
European Respiratory Journal · 2023
DOI: 10.1183/13993003.01245-2022 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Sachin Chaudhary und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of Arizona, Tucson, AZ, USA. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background
A genomic classifier for usual interstitial pneumonia (gUIP) has been shown to predict histological UIP with high specificity, increasing diagnostic confidence for idiopathic pulmonary fibrosis (IPF). Whether those with positive gUIP classification exhibit a progressive, IPF-like phenotype remains unknown.
Methods
A pooled, retrospective analysis of patients who underwent clinically indicated diagnostic bronchoscopy with gUIP testing at seven academic medical centres across the USA was performed. We assessed the association between gUIP classification and 18-month progression-free survival (PFS) using Cox proportional hazards regression. PFS was defined as the time from gUIP testing to death from any cause, lung transplant, ≥10% relative decline in forced vital capacity (FVC) or censoring at the time of last available FVC measure. Longitudinal change in FVC was then compared between gUIP classification groups using a joint regression model.
Results
Of 238 consecutive patients who underwent gUIP testing, 192 had available follow-up data and were included in the analysis, including 104 with positive gUIP classification and 88 with negative classification. In multivariable analysis, positive gUIP classification was associated with reduced PFS (hazard ratio 1.58, 95% CI 0.86–2.92; p=0.14), but this did not reach statistical significance. Mean annual change in FVC was −101.8 mL (95% CI −142.7– −60.9 mL; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, University of Arizona, Tucson, AZ, USA.
- Division of Pulmonary and Critical Care Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
- Department of Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, USA.
- Division of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
- Division of Pulmonary, Critical Care and Sleep Medicine, University of California at Davis, Sacramento, CA, USA.
- Division of Pulmonary and Critical Care and Sleep Medicine, National Jewish Health, Denver, CO, USA.
ORCID-Profile: Janelle Vu Pugashetti
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Chaudhary, S., Weigt, S. S., Ribeiro Neto, M. L., Benn, B. S., Pugashetti, J. V., Keith, R., Chand, A., Oh, S., Kheir, F., Ramalingam, V., Solomon, J. J., Harper, R., Lasky, J. A., & Oldham, J. M. (2023). Interstitial lung disease progression after genomic usual interstitial pneumonia testing. European Respiratory Journal. https://doi.org/10.1183/13993003.01245-2022
Vancouver
Chaudhary S, Weigt SS, Ribeiro Neto ML, Benn BS, Pugashetti JV, Keith R, et al. Interstitial lung disease progression after genomic usual interstitial pneumonia testing. European Respiratory Journal. 2023. doi:10.1183/13993003.01245-2022
BibTeX
@article{Chaudhary2023,
author = {Chaudhary, Sachin and Weigt, S Sam and Ribeiro Neto, Manuel L and Benn, Bryan S and Pugashetti, Janelle Vu and Keith, Rebecca and Chand, Arista and Oh, Scott and Kheir, Fayez and Ramalingam, Vijaya and Solomon, Joshua J and Harper, Richart and Lasky, Joseph A and Oldham, Justin M},
title = {Interstitial lung disease progression after genomic usual interstitial pneumonia testing},
journal = {European Respiratory Journal},
year = {2023},
doi = {10.1183/13993003.01245-2022}
}
EUVIMED